Clinical trial
An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
NCT04671849 is registered in ClinicalTrials.gov with Jiangsu Simcere Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 21, 2020
- Completion date
- March 16, 2023
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced or metastatic solid tumors with ntrk, ros1 or alk gene fusion